troglitazone has been researched along with Amyloidosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Amyloidosis: A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fortin, JS | 1 |
| Benoit-Biancamano, MO | 1 |
1 other study available for troglitazone and Amyloidosis
| Article | Year |
|---|---|
In vitro evaluation of hypoglycemic agents to target human islet amyloid polypeptide: a key protein involved in amyloid deposition and beta-cell loss.
Topics: Amyloid; Amyloidosis; Animals; Carbamates; Cell Survival; Chromans; Circular Dichroism; Glyburide; H | 2015 |